In vitro activity and durability of a combination of an antibiofilm and an antibiotic against vascular catheter colonization

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 621-625

  Mansouri, Mohammad D ^a,b   Hull, Richard A ^a   Stager, Charles E ^a,b   Cadle, Richard M ^a,b   Darouiche, Rabih O ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; LEVOFLOXACIN; LEVOFLOXACIN PLUS N ACETYLCYSTEINE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BACTERIUM ISOLATE; BIOFILM; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DRUG EFFECT; DRUG STABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL;

ACETYLCYSTEINE; ANTI-INFECTIVE AGENTS; BIOFILMS; COLONY COUNT, MICROBIAL; DRUG COMBINATIONS; EQUIPMENT CONTAMINATION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; OFLOXACIN; VASCULAR ACCESS DEVICES;

EID: 84872026729     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01646-12     Document Type: Article

References (39)

1. Crnich CJ, Maki DG. 2001. The role of intravascular devices in sepsis. Curr. Infect. Dis. Rep. 3:496-506.
2. Darouiche R, Raad I, Heard S, Thornby J, Wenker O, Gabrielli A, Berg J, Khardori N, Hanna H, Hachem R, Harris R, Mayhall G. 1999. A comparison of two antimicrobial-impregnated central venous catheters. N. Engl. J. Med. 340:1-8.
3. Kluger DM, Maki DG. 1999. The relative risk of intravascular device related bloodstream infection in adults, p 514. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. American Society for Microbiology, Washington, DC.
4. Maki D, Mermel M. 1998. Infections due to infusion therapy, p 689-724. In Bennett JV, Brachman PS (ed), Hospital infections, 4th ed. Lippincott-Raven, Philadelphia, PA.
5. O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph A, Rupp ME, Saint S, Healthcare Infection Control Practices Advisory Committee (HICPAC). 2011. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention, Atlanta, GA.
6. Maki DG. 1994. Infections caused by intravascular devices used for infusion therapy: pathogenesis, prevention, and management, p 155-212. In Bisno AL, Waldovogel FA (ed), Infections associated with indwelling medical devices, 2nd ed. American Society for Microbiology, Washington, DC.
7. Costerton JW, Montanaro L, Arciola CR. 2005. Biofilm in implant infections: its production and regulation. Int. J. Artif. Organs 28:1062-1068.
8. Danese PN. 2002. Antibiofilm approaches: prevention of catheter colonization. Chem. Biol. 9:873-880.
9. Olofsson AC, Hermansson M, Elwing H. 2005. Use of a quartz crystal microbalance to investigate the antiadhesive potential of N-acetyl-L-cysteine. Appl. Environ. Microbiol. 71:2705-2712.
10. Donelli G. 2006. Vascular catheter-related infection and sepsis. Surg. Infect. (Larchmt.) 7(Suppl 2):S25-S27.
11. Fraenkel D, Rickard C, Thomas P, Faoagali J, George N, Ware R. 2006. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit. Care. Med. 34:668-675.
12. Hanna H, Bahna P, Reitzel R, Dvorak T, Chaiban G, Hachem R, Raad I. 2006. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob. Agents Chemother. 50:3283-3288.
13. Hockenhull JC, Dwan K, Boland A, Smith G, Bagust A, Dündar Y, Gamble C, McLeod C, Walley T, Dickson R. 2008. The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation. Health Technol. Assess. 12:1-154.
14. Agarwal G, Kapil A, Kabra SK, Das BK, Dwivedi SN. 2005. In vitro efficacy of ciprofloxacin and gentamicin against a biofilm of Pseudomonas aeruginosa and its free-living forms. Natl. Med. J. India 18:184-186.
15. Siegrist HH, Nepa MC, Jacquet A. 1999. Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study. J. Antimicrob. Chemother. 43(Suppl C):51-54.
16. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. 2006. Tigecycline: a novel glycylcycline antibiotic. Expert Rev. Anti Infect. Ther. 4:9-25.
17. Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. 1991. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann. Emerg. Med. 20:1058-1063.
18. Soldini D, Zwahlen H, Gabutti L, Marzo A, Marone C. 2005. Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. Eur. J. Clin. Pharmacol. 60:859-864.
19. Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito AM. 2003. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int. J. Antimicrob. Agents 22(Suppl 2):95-100.
20. Olofsson AC, Hermansson M, Elwing H. 2003. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl. Environ. Microbiol. 69:4814-4822.
21. Yuta A, Baraniuk JN. 2005. Therapeutic approaches to mucus hypersecretion. Curr. Allergy Asthma Rep. 5:243-251.
22. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ, Hurtado C, Blanco MT, Gomez-Garcia AC. 1997. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J. Antimicrob. Chemother. 39:643-646.
23. Schwandt LQ, Van Weissenbruch R, Stokroos I, Van der Mei HC, Busscher HG, Albers FW. 2004. Prevention of biofilm formation by dairy products and N-acetylcysteine on voice prostheses in an artificial throat. Acta Otolaryngol. 124:726-731.
24. Mansouri MD, Darouiche RO. 2007. In vitro antimicrobial activity of N-acetylcysteine against bacteria colonising central venous catheters. Int. J. Antimicrob. Agents. 29:474-476.
25. Mansouri MD, Darouiche RO. July 2003. Method for treating medical devices using glycerol and an antimicrobial agent. US patent 6,589,591.
26. Bassetti S, Hu J, D'Agostino RB, Sherertz RJ. 2001. Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo. Antimicrob. Agents Chemother. 45:1535-1538.
27. Mansouri MD, Boone TB, Darouiche RO. 2009. Comparative assessment of antimicrobial activities of antibiotic-treated penile prostheses. Eur. Urol. 56:1039-1045.
28. Mansouri MD, Darouiche RO. 2008. In-vitro activity and in-vivo efficacy of catheters impregnated with chloroxylenol and thymol against uropathogens. Clin. Microbiol. Infect. 14:190-192.
29. Sherertz RJ, Forman DM, Solomon DD. 1989. Efficacy of dicloxacillin-coated polyurethane catheters in preventing subcutaneous Staphylococcus aureus infection in mice. Antimicrob. Agents Chemother. 33:1174-1178.
30. Larsen T, Fiehn NE. 1995. Development of a flow method for susceptibility testing of oral biofilms in vitro. APMIS 103:339-344.
31. Nickel JC, Wright JB, Ruseska I, Marrie TJ, Whitfield C, Costerton JW. 1985. Antibiotic resistance of Pseudomonas aeruginosa colonizing a urinary catheter in vitro. Eur. J. Clin. Microbiol. 4:213-218.
32. Schultz CL, Pezzutti MR, Silor D, White R. 1995. Bacterial adhesion measurements on soft contact lenses using a Modified Vortex Device and a Modified Robbins Device. J. Ind. Microbiol. 15:243-247.
33. Camargo GM, Pizzolitto AC, Pizzolitto EL. 2005. Biofilm formation on catheters used after cesarean section as observed by scanning electron microscopy. Int. J. Gynaecol. Obstet. 90:148-149.
34. Raad II, Hanna H, Maki D. 2007. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect. Dis. 7:645-657.
35. Richards MJ, Edwards JR, Culver DH, Gaynes RP. 1999. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infection Surveillance System. Crit. Care Med. 27:887-892.
36. Digiovine B, Chenoweth C, Watts C, Higgins M. 1999. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am. J. Respir. Crit. Care Med. 160:976-981.
37. Pittet D, Tarara D, Wenzel RP. 1994. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 271:1598-1601.
38. Safdar N, Fine JP, Maki DG. 2005. Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann. Intern. Med. 142:451-466.
39. Brown J, Doloresco F, III, Mylotte JM. 2009. "Never events": not every hospital acquired-infection is preventable. Clin. Infect. Dis. 49:743-746.